期刊文献+

阿霉素脂质体的制备及其体外抗肿瘤活性的初步研究 被引量:2

The Preparation of Adriamycin Liposome and the Preliminary Research of its Anti-tumor Activity in Vitro
原文传递
导出
摘要 目的:应用超声波分散法制备脂质体阿霉素,并比较脂质体阿霉素与游离性阿霉素抗肿瘤活性。方法:以卵磷脂和胆固醇为原料,将阿霉素包封于脂质体中,采用超声分散法制备脂质体阿霉素,对其在290-700nm范围内进行紫外扫描,用SephedexG-50柱分离脂质体阿霉素并计算其包封率。以昆明种小鼠为载体建立肿瘤模型(S180型肉瘤)和细胞荧光染色法研究脂质体阿霉素的抗肿瘤活性,以ZITA SIZER3000型表面电位与粒度测定仪测定其粒径分布。结果:脂质体阿霉素在480nm处有最大吸收峰值,包封率达91.3%,细胞荧光染色显示,脂质体及游离型阿霉素均对S180细胞有明显的抑制作用。结论:此法制备的脂质体阿霉素包封率高,粒径分布集中,脂质体阿霉素较游离型阿霉素有较强的抗肿瘤活性剂及较低的细胞毒作用,对阿霉素的临床应用有一定的参考价值。 Objective: To apply ultrasonic dispersion method to prepare adriamycin liposome, and compare the antitumor activity of adriamycin liposome and free doxoruhicin, Methods: As Lecithin and cholesterol as raw materials, the adriamycin was encapsulated in the liposomes, with in 290-700 nm uv scanning and SephedexG-50 column separation of adriamycin liposome, the coating rate is calculated. Taking Kunming mice as carrier to establish tumor model and cell fluorescent staining method to study the antitumor activity of the driamycin liposome, making use of ZITA SIZER3000 Surface potential and granularity cryoscope to determine the particle size distribution. Results: Adriamycin liposome has maximum absorption peak at 480 nm, and the encapsulation rate was 91.3%, the cell fluorescence staining showed that liposomes and free type of doxombicin has obvious inhibitory effect on S180 cells. Conclusions: This method of preparation of liposomes doxombicin coating rate is high and has particle size distribution, the adriamycin liposome doxorubicin has strong antitumor active agent and low cytotoxic effect, and has certain reference value for the clinical application of doxorubicin.
出处 《现代生物医学进展》 CAS 2014年第26期5054-5057,共4页 Progress in Modern Biomedicine
关键词 阿霉素 脂质体 制备 抗肿瘤 Adriamycin Liposomes Preparation Antitumor
  • 相关文献

参考文献9

二级参考文献57

共引文献121

同被引文献28

  • 1Orlowski R Z,Voorhees P M,Garcia R A,et al.Phase I trial ofthe proteasome inhibitor bortezomib and pegy Lated liposomal doxorubi-ein in patients with advanced hematologic malignancies[J].Blood,2005,105(8):3058-3065.
  • 2Visani G,Guiducci B,D’ Adamo F,et al.Cyclophosphamide,pegylated liposome doxorubicin,vincristine and prednisone(GDOP) plusrituximab is effective and well tolerated in poor performancestatus elderly patients with Non-Hodgkin lymphoma[J].Leukemia lymphoma,2005,46(3):477-479.
  • 3Illidge T,Specht L,Yahalom J,et al.Modern radiation therapy for nodal non-hodgkin lymphoma-target definition and dose guidelines from the international lymphoma radiation oncology group[J].Int J Radiat Oncol Biol Phys,2014,89(1):49-58.
  • 4Strobbe L,Van der Schans,S A,Heijker S,et al.Evaluation of a panel of expert pathologists:review of the diagnosis and histological classification of Hodgkin and non-Hodgkin lymphomas in a population-based cancer registry[J].Leukemia and lymphoma,2014,55(5):1018-1022.
  • 5Hagemeister F B,Rodriguez M A,Deitcher S R,et al.Long term results of a phase 2 study of vincristine sulfate liposome injection(MarqiboR) substituted for non-liposomal vincristine in cyclophosphamide,doxorubicin,vincristine,prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas[J].Blood,2013,122(21):3033.
  • 6Deng Z,Yan F,Jin Q,et al.Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposome-microbubble complexes assisted by ultrasound[J].J Control Release,2014,174(1):109-116..
  • 7李燕,陶敏,段卫明,王振欣,戴云,王蓉.隐匿性脂质体阿霉素联合奥沙利铂和卡培他滨治疗晚期胃癌疗效观察[J].中国医师进修杂志,2009,32(3):41-43. 被引量:3
  • 8贾晋斌,韦青燕.阿霉素脂质体的研究进展[J].中国肿瘤,2011,20(5):372-377. 被引量:18
  • 9刘俊茹,李娟,陈媚,黄蓓晖,谷景立.硼替佐米+脂质体阿霉素+地塞米松方案治疗多发性骨髓瘤临床观察[J].实用医院临床杂志,2011,8(4):18-21. 被引量:8
  • 10曾四元,李凌,钟美玲,江维,吴云燕,刘毅.紫杉醇脂质体联合铂类同步放化疗治疗宫颈癌的随机对照研究[J].中华肿瘤杂志,2011,33(7):517-519. 被引量:31

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部